Remdesivir – which was used to treat Trump – has ‘little effect’ on a COVID patient’s chances of survival, WHO study finds
- The antiviral remdesivir is one of only two COVID-19 treatments that has received emergency FDA approval in the United States.
- WHO trial involving 11,266 hospital patients with COVID-19 tested treatments with remdesivir, hydroxychloroquine, lopinavir and interferon
- The SOLIDARITY trial found that none of the four “substantially affected” death rates
Remdesivir does not improve chances of survival from COVID-19, a large-scale World Health Organization (WHO) trial and three other treatments have ruled.
More than 11,200 COVI-19 hospital patients worldwide have been treated with remdesivir – an antiviral – lopinavir, hydroxychloroquine, interferon or a placebo for the massive WHO SOLIDARITY trial, according to the Financial Times.
None of the drugs “substantially affected” the risk of death, according to the sad report.
It is a blow to the hope that the world will improve in treating those sick by the pandemic which has claimed the lives of more than a million people worldwide, including more than 217,000 in the United States. United.
SOLIDARITY’s results are particularly grim news for the United States, where remdesivir is one of two treatments to have received emergency clearance from the Food and Drug Administration (FDA).
US government research has suggested the drug improves chances of survival and shortens recovery times.
The federal government has already built up a drug supply, and regulators revoked emergency approval of another drug found ineffective to treat the coronavirus by the WHO trial, hydroxychloroquine, in June.
This is a developing story.
Massive WHO study found remdesivir had no significant effect on risk of death from COVID-19